Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆijªÁø     (Date : 2016-07-13 10:21:03)
Á¦¸ñ [³í¹®] [2014]Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
³»¿ë


J Surg Oncol. 2014 Sep;110(3):245-51. doi: 10.1002/jso.23646. Epub 2014 May 29.

Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

Kim TJ1Park CKYeo CDPark KRhee CKKim JKim SJLee SHLee KYYoon HK.

Author information

Abstract

BACKGROUND:

Simultaneous genotyping has advantages in turnaround time and detecting the real mutational prevalence in unresectable non-small-cell lung cancer (NSCLC), a group not previously genetically characterized.

METHODS:

We developed simultaneous panel of screening EGFR and KRAS mutations by direct sequencing or PNA clamping, and ALK rearrangement by fluorescent in situ hybridization (FISH) in multicenter manner.

RESULTS:

Of 510 NSCLC Korean patients, simultaneous genotyping identified mutations of EGFR (29.0%) and KRAS (8.6%) and rearrangement of ALK (9.2%). Seven patients had overlaps in mutations. Although several well-known associations between genotypes and clinical characteristics were identified, we found no relationship between ALK rearrangement and sex or smoking history. Unlike the other genotype mutations, ALK rearrangement was associated with advanced disease. Among the ALK-negative group, patients with 10-15% of ALK FISH split shared characteristics, such as younger age and advanced stage disease, more with the ALK-positive group (>15% ALK FISH split) than <10% ALK FISH split group.

CONCLUSIONS:

Simultaneous panel genotyping revealed more prevalent ALK rearrangements than reported in previous studies and their strong association with advanced stage irrespective of sex or smoking history. ALK rearrangement seems to be a marker for aggressive tumor biology and should be assessed in advanced disease.

© 2014 Wiley Periodicals, Inc.


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆijªÁø 28900
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆijªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆijªÁø 29235
   46           [³í¹®] [2015]Simultaneous genoty.. ÆijªÁø 6093
¢º           [³í¹®] [2014]Simultaneous diagno.. ÆijªÁø 21001
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆijªÁø 8149
   43           [³í¹®] [2013]Detection of EGFR m.. ÆijªÁø 1201
   42           [³í¹®] [2013]Detection and compa.. ÆijªÁø 5841
   41           [³í¹®] [2013]Detection of BRAF V.. ÆijªÁø 6121
   40           [³í¹®] [2013]Comparison of Direc.. ÆijªÁø 25312
   39           [³í¹®] [Microarray]Peptide nucle.. ÆijªÁø 14349
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆijªÁø 22269
   37           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆijªÁø 3413
   36           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆijªÁø 14184
   35           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆijªÁø 1191
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆijªÁø 4053
   33           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆijªÁø 8848
   32           [³í¹®] [ÆijªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆijªÁø 14502
   31           [³í¹®] [ÆijªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆijªÁø 1199
   30           [³í¹®] [ÆijªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆijªÁø 3919
 

< 1 2 3 >